These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1451723)

  • 41. [Metabolic fate of carteolol hydrochloride (OPC-1085), a new beta-adrenergic blocking agent. (6) Pharmacokinetics of carteolol in the rat, dog, rabbit and man].
    Morita S; Irie Y; Sakuragi S; Kori H
    Nihon Yakurigaku Zasshi; 1977 Mar; 73(2):229-35. PubMed ID: 328355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of renal insufficiency on the pharmacokinetics of cicletanine and its effects on the urinary excretion of electrolytes and prostanoids.
    Ferry N; Geoffroy J; Pozet N; Cuisinaud G; Benzoni D; Zech PY; Sassard J
    Br J Clin Pharmacol; 1988 Mar; 25(3):359-66. PubMed ID: 3358898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human urinary fluoride excretion as influenced by renal functional impairment.
    Schiffl HH; Binswanger U
    Nephron; 1980; 26(2):69-72. PubMed ID: 7412962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function.
    Maigaard S; Frimodt-Möller N; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1979 Sep; 16(3):411-6. PubMed ID: 507797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic and pharmacodynamic interactions among haloperidol, carteolol hydrochloride and biperiden hydrochloride.
    Isawa S; Murasaki M; Miura S; Yoshioka M; Uchiumi M; Kumagai Y; Aoki S; Hisazumi H; Kudo S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):111-8. PubMed ID: 10495985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function.
    Wong SL; Menacherry S; Mulford D; Schmitz PJ; Locke C; Granneman GR
    Eur J Clin Pharmacol; 1997; 52(3):223-7. PubMed ID: 9218930
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.
    Rouan MC; Binswanger U; Bammatter F; Theobald W; Schoeller JP; Guibert J
    J Antimicrob Chemother; 1984 Jun; 13(6):611-8. PubMed ID: 6088464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of TZU-0460, a new H2-receptor antagonist, in patients with impaired renal function.
    Takabatake T; Ohta H; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Satoh S; Hattori N
    Eur J Clin Pharmacol; 1986; 30(6):709-12. PubMed ID: 2876900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection.
    Roth S; Naber K; Scheer M; Gruenwaldt G; Lange H
    Eur J Clin Pharmacol; 1976 Sep; 10(5):357-65. PubMed ID: 789084
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tubulopathy with macroalbuminuria due to diabetic nephropathy and primary glomerulonephritis.
    Yaqoob M; McClelland P; Patrick AW; Stevenson A; Mason H; Bell GM
    Kidney Int Suppl; 1994 Nov; 47():S101-4. PubMed ID: 7869656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical aspects and renal function in patients with endemic nephropathy].
    Bukvić D; Djukanović L; Janković S
    Srp Arh Celok Lek; 2003; 131(1-2):10-6. PubMed ID: 14608855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dosage regimen of ranitidine in patients with renal impairment.
    Ebihara A; Ohashi K; Ikeda T; Yuhara M; Tagawa H; Yamakado M; Asano Y; Tabei K; Nakazawa K; Kondo K
    Int J Clin Pharmacol Res; 1989; 9(1):1-7. PubMed ID: 2707920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
    Takimoto CH; Graham MA; Lockwood G; Ng CM; Goetz A; Greenslade D; Remick SC; Sharma S; Mani S; Ramanathan RK; Synold TW; Doroshow JH; Hamilton A; Mulkerin DL; Ivy P; Egorin MJ; Grem JL
    Clin Cancer Res; 2007 Aug; 13(16):4832-9. PubMed ID: 17699862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
    Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L
    Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of renal resistive index among patients with Type 2 diabetes with different levels of creatinine clearance and urinary albumin excretion.
    Afsar B; Elsurer R
    Diabet Med; 2012 Aug; 29(8):1043-6. PubMed ID: 22269249
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased urinary excretion of alpha1-microglobulin at 6 months after transplantation is associated with urinary excretion of transforming growth factor-beta1 and indicates poor long-term renal outcome.
    Teppo AM; Honkanen E; Finne P; Törnroth T; Grönhagen-Riska C
    Transplantation; 2004 Sep; 78(5):719-24. PubMed ID: 15371675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The renal kallikrein-kinin system in renoparenchymal hypertension.
    Ando T; Shimamoto K; Ura N; Yokoyama T; Fukuyama S; Yamaguchi Y; Nakagawa H; Mori Y; Ogata H; Iimura O
    Adv Exp Med Biol; 1989; 247B():127-32. PubMed ID: 2610051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment.
    Jungheinrich C; Scharpf R; Wargenau M; Bepperling F; Baron JF
    Anesth Analg; 2002 Sep; 95(3):544-51, table of contents. PubMed ID: 12198032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effects of glucose ingestion on urinary excretion of electrolytes: comparison between patients with chronic glomerulonephritis and diabetes mellitus].
    Minami M; Yagi N; Ishiyama A; Nagoshi H; Igari T; Ishii K; Nishiyama K
    Nihon Jinzo Gakkai Shi; 1995 Apr; 37(4):231-7. PubMed ID: 7602810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.